ADC and Radiopharmaceuticals Pharma and Biotech Partnering Summit

Temas de la conferencia
Major moves in the pharma and biotech partnering are reshaping the landscape. With AbbVie's acquisition of ImmunoGen leading the charge in 2023, and Merck's licensing deal with Daiichi reaching unprecedented heights across three ADC programs, the market frenzy surrounding ADCs has never been hotter.

Even Eli Lilly's acquisition of Mablink, despite lacking clinical programs, underscores the feverish pace of activity in the field, breaking traditional pharma partnering trends.

Organizador profesional (PCO)
Hanson Wade

Observaciones
URL:
Brochure: https://go.evvnt.com/2481194-3?pid=4832

Speakers: Adrianne Wong, Director, Oncology Search and Evaluation, Global Business Development, Daiichi Sankyo, Albert Hsia, Executive Director, Business Development, Merck, and more

https://go.evvnt.com/2481194-2?pid=4832

Ms. Karina Bikerniece